Liraglutide

19 March, 2026 - Press Release Download attachment Nanexa’s atomic layer deposition (ALD)‑based PharmaShell® platform enables an unprecedented pharmacokinetic profile for semaglutide, also supporting the potential for once‑quarterly administration. New preclinical data shows ultra‑long release indicating an exceptionally smooth plasma concentration profile for repeated quarterly dosing in human PK simulations The results strengthen Nanexa’s position in the rapidly evolving metabolic disease treatment landscape and reinforce the company’s ability to secure new commercial collaborations. Nanexa AB today announces highly promising new results from its long‑acting semaglutide program, developed using the company’s proprietary PharmaShell® drug delivery platform. Building on the breakthrough monthly‑dosing PK data reported in January 2026, Nanexa has now completed a pharmacokinetic study in rats using several PharmaShell® semaglutide formulations. These new data, in combination with human modelling, indicate that semaglutide can potentially be administered once every three months (quarterly) while maintaining a controlled and therapeutically relevant plasma concentration. PharmaShell® encases active pharmaceutical ingredients at the atomic level in a highly protective, extremely thin film coating (approximately 30 nm thick) of slow-dissolving non-toxic inorganic oxides. The platform provides exceptional control of release rate, enabling long, smooth PK profiles with very low ratio between the maximum and minimum plasma concentration. New Rat Data Supports Ultra‑Long Release with Exceptionally Smooth Plasma Concentration Profile Using this dataset, Nanexa applied established pharmacokinetic models to simulate repeated dosing in humans. These simulations demonstrate that PharmaShell®‑coated semaglutide can achieve and maintain therapeutic plasma levels using once‑quarterly subcutaneous injections, with ratio between the maximum and minimum plasma concentration significantly lower than typically observed for weekly administration of the marketed product Wegovy® (semaglutide). Lower initial plasma concentration peaks are considered key to minimizing gastrointestinal side effects such as nausea — a major reason for treatment discontinuation in GLP‑1 therapies. By enabling a smoother and more tolerable exposure profile, PharmaShell® could markedly improve adherence and overall patient experience. A Major Step Forward for Long‑Acting GLP‑1 Therapies “These new results represent another important milestone for Nanexa,” said David Westberg, CEO of Nanexa. “Demonstrating the potential for quarterly dosing of semaglutide is exceptional, and — as far as we know — no one else has shown this before. This further underscore the unique capability of PharmaShell® to control release rates for complex peptides and reinforces our position as a leader in long‑acting GLP‑1 development. We see significant commercial and therapeutic potential in these findings.” The new data build on the clinical Phase 1 results from Nanexa’s liraglutide program, reported in 2025, which provided essential human validation of the PharmaShell® technology. These learnings have accelerated development, improved modelling accuracy, and strengthened the path toward clinical readiness. For additional information, please contact: David Westberg – CEO, Nanexa AB (publ) Phone: +46 70 942 83 03 Email: david.westberg@nanexa.se www.nanexa.com The company’s Certified Adviser is Tapper Partners AB. About Nanexa AB (publ) Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company’s proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of ‘super generic’ formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others. Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna. Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA). Attachments Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell®

FRIDAY, March 13, 2026 -- For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research letter published online March 11 in JAMA Network Open . Kuan-Yu Chi, M.D., from the Albert Einstein College of Medicine in Bronx, New York, and colleagues conducted a retrospective cohort study to examine the association between GLP-1 RA use and survival among patients with BM and T2D. The exposed cohort included adult patients prescribed GLP-1 RAs within six months before the first instance of T2D and BM diagnosis, while the control cohort had no GLP-1 RA use during the same period. After propensity score matching, a total of 850 GLP-1 RA users were matched to nonusers among a total of 19,234 patients with cancer, BM, and T2D. The researchers found that all-cause mortality was significantly lower in association with GLP-1 RA use (hazard ratio, 0.63). The observed mortality benefit was consistent across major cancer types and GLP-1 RA types, apart from liraglutide, and compared with other antidiabetes therapies. "These results build upon existing evidence that GLP-1 receptor activation modulates pathways relevant to neuro-oncologic health, including attenuation of neuroinflammation, preservation of blood-brain barrier integrity, and reduction of oxidative stress and mitochondrial dysfunction," the authors write. Abstract/Full Text